Updated on 22/04/2020

Curriculum Vitae Et Studiorum: Prof Alfonso Zambon

Personal data: Born in Venice 08 11 1972
Present Position: Associate Professor in Organic Chemistry
Address: Via G. Campi 103, 41125, Modena. Phone: +39 0590598640
Email:alfonso.zambon@unimore.it;alfonsozambon@gmail.com
Web site: https://uk.linkedin.com/in/alfonso-zambon-a4140358
ResearchID: http://www.researcherid.com/rid/J-2529-2012
ORCID ID: orcid.org/0000-0002-8074-2308

EDUCATION

- **1998** Degree in Chemistry summa cum laude at the University of Venice with a thesis entitled 'Studio delle proprieta' catalitiche di Cu,Zn Superossidodismutasi tramite tecniche polarografiche". under the supervision of Prof. E. Argese
- **2003** Ph. D. in Chemistry (Interuniversitary Consortium of Venice and Ferrara) with a thesis entitled 'Sintesi, caratterizzazione ed applicazioni di nuove molecole mono e oligomeriche a partire da substrati enantiomericamente puri ' under the supervision of Prof.V. Lucchini
-

PREVIOUS POSITIONS AND FELLOWSHIPS

- **27/11/2019- present** Università degli studi di Modena e Reggio Emilia
- Associate Professor of Organic Chemistry, SSD CHIM06
-
- **28/11/2016-27/11/2019** Università degli studi di Modena e Reggio Emilia
- Assistant Professor of Organic Chemistry (Tenure Track), SSD CHIM06
-
- **01/04/2014- 27/11/2016** Institute of Cancer Research, London, UK
- Senior Scientific Officer
-
- **01/10/2011- 01/04/2014** Institute of Cancer Research, London, UK
- Higher Scientific Officer
-
- **15/01/2007- 30/09/2011** Institute of Cancer Research, London, UK
- Postdoctoral Training Fellow
-
- **01/02/2005- 31/01/2006** University Claude Bernard-Lyon1, Lyon, France
- Post Doctoral Researcher
-
- **01/08/2000-14/01/2007** Università Ca' Foscari Venezia
- Graduate Technical Assistant

BRIEF DESCRIPTION OF RESEARCH ACTIVITY

I am an organic/medicinal chemist with experience in all phases of drug discovery, from hit identification to preclinical development.
My main research focus has been on the development of targeted anti-cancer agents by multiparametric PK/PD optimisation of inhibitors of intracellular and extracellular targets. I am co-author of over 45 peer-reviewed publications and patents and I contributed to the writing of various successful grant proposals for the funding of PhD studentships and early and late stage drug discovery programmes.
Current research interests include the development of bioactive hybrid organic-inorganic materials with modulable physico-chemical properties and the structure based design synthesis of multi-targeted kinase inhibitors and chemical probes.

MAJOR COLLABORATIONS

- Dipartimento di Scienze Chimiche e Geologiche (A.Gualtieri, G. Lusvardi, G. Vezzalini, R. Arletti, A. Mucci, E.Ferrari) and Dipartimento di Scienze Vita within the Università degli studi di Modena e Reggio Emilia (M. Rossi, F. Prati, G. Rastelli)
- Università di Milano Bicocca (L. Mologni)
- Università ca' Foscari Venezia (F. Fabris)
- Università di Padova (G. Marzaro)
- University of Keele (UK) (G. DiLeva)
- CRUK Manchester Institute (C. Springer, D. Niculescu-Duvaz)

FUNDING AND PROJECTS

- Wellcome Trust SDDI 2014-2017 "The late stage development of LOX inhibitors" (Partecipant)
- Wellcome Trust Studentship 2011-2015 "Synthesis and biological evaluation of CRAF inhibitors" (co-applicant)
- Wellcome Trust 2011-2016 Preclinical and clinical development of panRAF inhibitors" (Partecipant)
- Wellcome Trust SDDI 2009-2014 "Development of LOX inhibitors"
- Wellcome Trust 2006-2008 "Development of 2 series of systemic/oral inhibitors of BRAF in melanoma" (Partecipant)
- FAR2016 Dipartimentale "Molecular Factory: Sintesi Di Ftalocianine Funzionalizzate Per Dispositivi A Singola Molecola" (Co-Applicant)
- 2017- Progetto di Ateneo "Didattica per Competenze" (Partecipant)
-

TEACHING ACTIVITIES

- Università degli Studi di Modena e Reggio Emilia:
  - Lab Module of the "Organic Chemistry I" course for the I level degree in Chemistry, Academic Years 2016/2017, 2017/2018
  - "Organic Chemistry" for the I level degree in Natural Sciences, Academic Years 2017/2018- current titolare del corso "Chimica Organica" (Laurea Triennale in Scienze Naturali)
  - "Laboratory of Organic I" course for the I level degree in Chemistry, Academic Years 2018/2019)
- University of Salford (UK) 2018 & 2019 Modulo "Drug Discovery and Development-examples and case studies" (Master of Science "Drug Design and Discovery")

SUPERVISION OF PhD STUDENTS AND POSTDOCTORAL FELLOWS

- **2011-2015** Institute of Cancer Research, London, UK co Supervisor of Dr Alice Hooper, PhD Thesis “Development of Selective c-Raf inhibitors“ (2011- 2015).

MEMBERSHIPS AND APPOINTMENTS

- Member of the Division of Organic Chemistry of the Italian Chemical Society.
- Member of BARC- The British Association for Cancer Research and EACR- European Association for Cancer Research …
- Honorary Faculty, The Institute of Cancer Research, 2018

ACTIVITIES IN REFERRED SCIENTIFIC JOURNALS.

Reviewer for Journal of American Chemical Society, Experimental Dermatology, Endocrine, Journal of Clinical Endocrinology & Metabolism, Expert Opinion on Therapeutic Patents, Scientific Reports

SELECTED ORAL PRESENTATIONS

1) Università di Camerino, Italia "Team Based Learning per le Scienze: L'esperienza di Unimore" 2018
2) Convegno Potenzialità E Innovazione Nella Ricerca Biomedica: Approcci Interdisciplinari Modena, Italia "Sviluppo di probe molecolari per il riconoscimento e la quantificazione di biomarker in fluidi biologici" 2018
3) XXVI Congresso Nazionale della Società Chimica Italiana "Novel oligothiophenes with reduced HOMO-LUMO band gap for Optoelectonics" 2017
4) Università of Modena e Reggio Emilia " RAF inhibitors: form bench to bedside" 2017
5) Università of Padova, Italia "Development of panRAF inhibitors for the treatment of melanoma", 2014
6) Università of Geneva, Switzerland "Development of RAF inhibitors as anti-cancer agents", 2013
7) The Institute of Cancer Research, UK, "New BRAF inhibitors: exploration of distal aromatic groups", 2012
8) Lundbeck A/S, Copenhagen, Danimarca, "Development of oncogenic proteins inhibitors", 2011
9) Università Ca' Foscari Venezia, Italy, "Design and synthesis of novel BRAF inhibitors", 2009
10) FIS chemicals, Vicenza, Italy, "BRAF inhibitors as potential anti-melanoma agents", 2009
11) The Institute of Cancer Research, UK, "New BRAF inhibitors - optimisation of the 3233 series", 2008
12) Annual meeting of the Pharmaceutical Biochemistry Department of the University of Geneva, Sils Maria, Switzerland, "Palladium- catalysed cross coupling reactions as synthetic tools", 2006

OTHER INFORMATION

BIBLIOMETRIC INDICATORS (Scopus) AND SCIENTIFIC PRODUCTION

Total number of publications in scientific journals: 43
Total number of other publications:11
Total number of citations: 2145
h-index: 21
Average number of citations per publication: 50
Average number of citations per year: 110

TECHNOLOGICAL TRANSFER (Patents Granted)

1. Marais, R.; Springer, C.; Niculescu-Duvaz, D.; Miller, N.; Aljarah, M.; Zambon, A.; Leung, L.; Smithen, D.; Brown, M.; Tang, H.; "Preparation of N, N'-disubstituted 9, 9-dimethyl-3, 6-diazabicyclo[3.2.2] nonanes as lysyl oxidase inhibitors for treatment of cancer" **2019** WO 2019073251 Priority GB 2017-16871
2. Gambacorti Passerini, C.; Gunby, R. .; Zambon, A.; Scapozza, L.; Ahmed, S.; Goekjian, P.G.; Gueyrard, D.; Popowycz, F.; Schneider, C. "Antiproliferative compounds and therapeutic uses thereof" **2009** WO 2009121535 Priority EP 2008-6651
3. Zambon, A.; Niculescu-Duvaz, D.; Chubb, R.; Springer, C. J. "Process for the preparation of 8- (4-aminophenoxy) -4H-pyrido[2, 3-b] pyrazin-3-one derivatives" **2015** WO 2015075482 Priority GB 2013-20732 Granted as CN 105745210 (**2018**, B), EP 3074395 (**2018**, B1) US 9708317 (**2017**, B2), US 10100053 (**2018**, B2)
4. Springer, C.J.; Marais, R.; Girotti, R.; Niculescu-Duvaz, D.; Niculescu-Duvaz, I.; Zambon, A. "Preparation of 1- (5-tert-butyl-2-aryl-pyrazol-3-yl) -3- [2-fluoro-4- [(3-oxo-4H-pyrido[2, 3-b] pyrazin-8-yl) oxy] phenyl] urea derivatives as RAF inhibitors for treating cancer" **2015** WO 2015075483 Priority GB 2013-20729 Granted as AU 2014351571 (**2019**, B2), CN 105793260 (**2018**, B2), EP 3074396 (**2019**, B1), JP 6389529 (**2018**, B2), US 9725447 (**2017**, B2), (
5. Springer, C. J.; Niculescu-Duvaz, I.; Marais, R.; Niculescu-Duvaz, D.; Zambon, A.; Menard, D. "1-(5-tert-butyl-2-phenyl-2h-pyrazol-3-yl)-3-[2-fluoro-4-(1-methyl-2 oxo 2,3-dihydro-1H-imidazo[4,5-b]-7-yloxy)-phenyl]-urea and related compounds and their use in therapy" **2011** WO2011092469 Priority WO 2011-GB106 Granted as US 8815896 (**2014**, B2); CN 104945401 (**2017**, B2); US 9120789 (**2015**, B2); JP 5956653 (**2016**, B2); US 9439893 (**2016**, B2); US 9820976 (**2017**, B2), US 10167282 (**2019**, B2)
6. Springer, C. J.; Niculescu-Duvaz, D.; Niculescu-Duvaz, I.; Marais, R.; Suijkerbuijk, B. M. J. M.; Zambon, A.; Nourry, A.; Menard, D. "Preparation of pyrido[2,3-b]pyrazine-8-substituted compounds as RAF inhibitors" **2009** WO 2009077766 Priority WO 2008-GB4208 Granted as AU 2008337286 (**2014**, B2), KR 1665143 (**2016**, B1), EP 2229391 (**2014**, B1), CN 101945869 (**2014**, B), JP 5511680 (**2014**, B2), EA 19974 (**2014**, B2), US 8198279 (**2012**, B2), US 8546387 (**2013**, B2), US 8912191 (**2014**, B2), AU 2014253528 (**2016**, B2), US 9155737 (**2015**, B2), US 9540372 (**2017**, B2)
7. Gambacorti Passerini, C.; Gunby, R.H.; Zambon, A.; Scapozza, L.; Ahmed, S.; Goekjian, P. G.; Gueyrard, D.; Popowycz, F.; Schneider, C. "Preparation of heterocyclylthiazolylbenzene derivatives and analogs for use as antiproliferative agents" **2009** WO 2009130487 Priority EP 2008-6651 Granted as JP 5524173 (**2014**, B2)
8. Niculescu-Duvaz, I.; Zambon, A., Niculescu-Duvaz, D.; Whittaker, S.; Marais, R.; Springer, C.; "Preparation of substituted aryl-quinolyl ureas and amides and their use" **2009** WO 2009130487 Priority GB 2008-7609 Granted as US 8383816 (**2014**, B2), EP 2285805 (**2014**, B1),

PUBLIC ENGAGEMENT

- Regular supervision of up to 40 students for tutorial in Organic Chemistry during Open Days
- Implementation of Team Based Learning for the Organic Chemistry course in Natural Sciences

LIST OF SCIENTIFIC PUBLICATIONS ON INTERNATIONAL JOURNALS WITH IF.

1. Amaretti A., Russo B., Raimondi S., Leonardi A., Foca G., Mucci A., Zambon A., Rossi M., "Potential of Wickerhamomyces Anomalus in Glycerol Valorization", *Chemical Engineering Transactions,* **2020**, *79*, 19-24 DOI:10.3303/CET2079004

2. Zambon, A.; Righi, V.; Parenti, F.; Libertini, E.; Rossi, M. C.; Mucci, A. "Nucleoside 2',3'-cyclic monophosphates in Aphanizomenon flos-aquae detected through nuclear magnetic resonance and mass spectrometry" *J. Agr. Food Chem.,* **2019***, 67,* 12780-12785

3. Gualtieri, A. F.; Lusvardi, G.; Pedone, A.; Di Giuseppe, D.; Zoboli, A.; Mucci, A.; Zambon, A.; Filaferro, M.; Vitale, G.; Benassi, M.; Avallone, R.; Pasquali, L.; Lassinantti Gualtieri, M. "Structure Model and Toxicity of the Product of Biodissolution of Chrysotile Asbestos in the Lungs" *Chemical Research in Toxicology,* **2019,** *32*, 2063-2077

4. Nicolini, V.; Malavasi, G.; Lusvardi, G; Zambon, A.; Benedetti, F.; Cerrato, G.; Valeri, S.; Luches, P. "Mesoporous bioactive glasses doped with cerium: Investigation over enzymatic-like mimetic activities and bioactivity" *Ceramics International*, **2019,** *45*, 20910-20920

5. Leung, L.; Niculescu-Duvaz, D.; Smithen, D.; Lopes, F.; Callens, C.; McLeary, R.; Saturno, G.; Davies, L.; Aljarah, M.; Brown, M.; Johnson, L.; Zambon, A.; Chambers, T.; Ménard, D.; Bayliss, N.; Knight, R.; Fish L.; Lawrence, R.; Challinor, M.; Tang, H.; Marais, R.; Springer C "Anti-metastatic Inhibitors of Lysyl Oxidase (LOX):Design and Structure-Activity Relationships" *J. Med. Chem.*; **2019**, 62, 5863-5884

6. Malavasi, G.; Salvatori, R.; Zambon, A.; Lusvardi, G.; Rigamonti, L.; Chiarini, L.; Anesi, A."Cytocompatibility of potential bioactive cerium-doped glasses based on 45S5" *Materials*, **2019**, *12*, 594-619

7. Hooper, A.; Zambon, A.; Springer, C. J. "A novel protocol for the one-pot borylation/Suzuki reaction provides easy access to hinge-binding groups for kinase inhibitors" *Org. Biomol. Chem.,* **2016**, *14*, 963-969

8. Girotti M.R.; .; Lopes, F.; Preece, N.; Niculescu-Duvaz, D.; Zambon, A; Davies, L.; Whittaker, S.; Saturno, G.; Viros, A.; Pedersen, M.; Suijkerbuijk, B.M.J.M.; Menard, D.; McLeary, R.; Johnson, L.; Fish, L.; Ejiama, S.; Sanchez-Laorden, B.; Hohloch, J.; Carragher, N.; MacLeod, K.; Ashton, G.; Marusiak, A.A.; Fusi, A.; Brognard, J.; Frame, M.; Lorigan, P; Marais, R.; Springer, C. J. "Paradox-Breaking RAF Inhibitors that Also Target SRC Are Effective in Drug-Resistant BRAF Mutant Melanoma" *Cancer Cell,* **2015**, *1*, 85-96

9. Sanchez-Laorden, B.; A. Viros; Girotti M.R.; Pedersen, M.; Saturno, G.; Zambon, A; Niculescu-Duvaz, D.; Turajlic, S.; Hayes, A; Gore, M.; Larkin, J.; Lorigan, P.; Cook, M.; Springer, C. ; Marais, R. " BRAF Inhibitors Induce Metastasis in RAS Mutant or Inhibitor-Resistant Melanoma Cells by Reactivating MEK and ERK Signaling" *Sci. Signal.,* **2014**, 7, p. ra 30

10. Girotti, M. R.; Pedersen, M.; Sanchez-Laorden, B.; Viros, A.; Turajlic, S.; Niculescu-Duvaz, D.; Zambon, A.; Sinclair, J.; Hayes, A.; Gore, M.; Lorigan, P.; Springer, C.; Larkin, J.; Jorgensen, C.; Marais, R. "Inhibiting EGF Receptor or SRC Family Kinase Signaling Overcomes BRAF Inhibitor Resistance in Melanoma" *Cancer Discov*, **2013**, *3*, 158-167

11. Niculescu-Duvaz, D.; Niculescu-Duvaz, I.; Suijkerbuijk, B.M.J.M.; Menard, D.; Zambon, A.; Davies, L.; Pons, J. F.; Whittaker, S.; Marais, R.; Springer, C. J. "Potent BRAF kinase inhibitors based on 2,4,5-trisubstituted imidazole with naphthyl and benzothiophene 4-substituents" *Bioorg. Med. Chem.*; **2013**; *21*; 1284-1304

12. Zambon, A.; Niculescu-Duvaz, D.; Niculescu-Duvaz, I.; Marais, R.; Springer, C.J. "BRAF as a therapeutic target: a patent review (2006 - 2012)" *Expert Opinion on Therapeutic Patents,* **2013**, *23*, 155-164

13. Viros A.; Hayward, R.; Yashar, S.; Yu, C.C.; Martin, M.; Zambon, A.; Niculescu-Duvaz, D.; Springer, C.J.; Lo, R.S.; Marais, R. "Topical 5-fluorouracil elicits regressions of BRAF inhibitor-induced cutaneous squamous cell carcinoma." *J. Invest. Dermatol.*, **2013**; *133*; 274-276

14. Su, F.; Viros A.; Milagre, C.; Trunzer, K.; Bollag, G.; Spleiss, O.; Reis-Filho, J.S.; Kong, X.; Koya, R.C.; Flaherty, K.T.; Chapman, P.B.; Kim, M.J.; Hayward, R.; Martin, M.; Yang, H.; Wang, Q.; Hilton, H.; Hang, J.S.; Noe, J.; Lambros, M.; Geyer, F.; Dhomen, N.; Niculescu-Duvaz, I.; Zambon, A.; Niculescu-Duvaz, D.; Preece, N.; Robert, L.; Otte, N.J.; Mok, S.; Kee, D.; Ma, Y.; Zhang, C.; Habets, G.; Burton, E.A.; Wong, B.; Nguyen, H.; Kockx, M.; Andries, L.; Lestini, B.; Nolop, K.B.; Lee, R.J.; Joe, A.K.; Troy, J.L.; Gonzalez, R.; Hutson, T.E.; Puzanov, I.; Chmielowski, B.; Springer, C.J.; McArthur, G.A.; Sosman, J.A.; Lo, R.S.; Ribas, A.; Marais, R. "RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors" *New Engl. J. Med.*; **2012**; *366*; 207-215

15. Zambon, A.; Niculescu-Duvaz, I.; Niculescu-Duvaz, D.; Marais, R.; Springer, C.J. "Small molecule inhibitors of BRAF in clinical trials" *Bioorg. Med. Chem. Lett*; **2012**; *22;* 789-792

16. Whittaker, S.; Ménard, D.; Kirk, R.; Ogilvie, L.; Hedley, D.; Zambon, A.; Lopes, F.; Preece, N. P. U.; Manne, H.; Rana, S.; Lambros, M.; Reis-Filho, J. S.; Marais, R.; Springer, C. J. " A Novel, Selective, and Efficacious Nanomolar Pyridopyrazinone Inhibitor of ^{V600E}BRAF" *Cancer Res.*; **2010**; *70*; 8036-44

17. Niculescu-Duvaz, D.; Niculescu-Duvaz, I.; Suijkerbuijk, B. M. J. M.; Ménard, D.; Zambon, A.; Nourry, A.; Davies, L.; Manne, H.; Friedlos, F.; Ogilvie, L.; Hedley, D.; Takle, A.; Wilson, D. M.; Pons, J.F.; Coulter, T.; Kirk, R.; Cantarino, N.; Whittaker, S.; Marais, R.; Springer, C. J. " Novel tricyclic pyrazole BRAF inhibitors with imidazole or furan central scaffolds" *Bioorg. Med. Chem.*; **2010**; *18*; 6934-6952

18. Whittaker, S.; Kirk, R.; Hayward, R.; Zambon, A.; Viros, A.; Cantarino, N.; Affolter, A.; Nourry, A.; Niculescu-Duvaz, D.; Springer, C. J.; Marais, R." Gatekeeper mutations mediate resistance to BRAF-targeted therapies" *Sci. Transl. Med. .*; **2010**; 35; p. 35ra41

19. Zambon, A.; Ménard, D.; Suijkerbuijk, B. M. J. M.; Niculescu-Duvaz, I.; Whittaker, S.; Niculescu-Duvaz, D.; Nourry, A.; Davies, L.; Manne, H.; Lopes, F.; Preece, N. P. U.; Hedley, D.; Ogilvie, L.; Kirk, R.; Marais, R;. Springer, C. J. " Novel Hinge Binder Improves Activity and Pharmacokinetic Properties of BRAF Inhibitors" *J. Med. Chem.*; **2010**; *53*, 5639-5655

20. Mologni, L.; Rostagno, R.; Brussolo, S.; Knowles, P. P.; Kjaer, S.; Murray-Rust, J.;

Rosso, E.; Zambon, A.; Scapozza, L.; McDonald, N. Q.; Lucchini, V.; Gambacorti-Passerini, C. " Synthesis, structure-activity relationship and crystallographic studies of 3-substituted indolin-2-one RET inhibitors" *Bioorg. Med. Chem.*; **2010**; *18*; 1482-1496

21. Nourry, A.; Zambon, A.; Davies, L.; Niculescu-Duvaz, I.; Dijkstra, H. P.; Ménard, D.; Gaulon, C.; Niculescu-Duvaz, D.; Suijkerbuijk, B. M. J. M.; Friedlos, F.; Manne, H.; Kirk, R.; Whittaker, S.; Marais, R;. Springer, C. J. " BRAF inhibitors based on an imidazo[4,5]pyridin-2-one scaffold and a meta substituted middle ring" *J. Med. Chem.*; **2010**; *53*, 1964-1978

22. Suijkerbuijk, B. M. J. M.; Niculescu-Duvaz, I.; Gaulon, C.; Dijkstra, H. P.; Niculescu-Duvaz, D.; Ménard, D.; Zambon, A.; Nourry, A.; Davies, L.; Manne, H.; Friedlos, F.; Ogilvie, L.; Hedley, D.; Lopes, F.; Preece, N. P. U.; Moreno-Farre, J.; Raynaud, F. I.; Kirk, R.; Whittaker, S.; Marais, R;. Springer, C. J. " The Development of Novel, Highly Potent Inhibitors of V-RAF murine sarcoma viral oncogene homolog B1 (BRAF): Increasing Cellular Potency through Optimization of a Distal Heteroaromatic Group" *J. Med. Chem.*; **2010**; *53*, 2741-2756

23. Ménard, D.; Niculescu-Duvaz, I.; Dijkstra, H. P.; Niculescu-Duvaz, D.; Suijkerbuijk, B. M. J. M.; Zambon, A.; Nourry, A.; Roman, E.; Davies, L.; Manne, H.; Friedlos, F.; Kirk, R.; Whittaker, S.; Gill, A.; Taylor, R. D.; Marais, R;. Springer, C. J. "Novel Potent BRAF Inhibitors: Toward 1 nM Compounds through Optimization of the Central Phenyl Ring" *J. Med. Chem.*; **2009**; *52*, 3881-3891

24. Niculescu-Duvaz, D.; Gaulon, C.; Dijkstra, H. P.; Niculescu-Duvaz, I.; Zambon, A.; Ménard, D.; Suijkerbuijk, B. M. J. M.; Nourry, A.; Davies, L.; Manne, H.; Friedlos, F.; Ogilvie, L.; Hedley, D.; Whittaker, S.; Kirk, R.; Gill, A.; Taylor, R. D.; Raynaud, F. I.; Moreno-Farre, J.; Marais, R;. Springer, C. J. " Pyridoimidazolones as Novel Potent Inhibitors of v-Raf Murine Sarcoma Viral Oncogene Homologue B1 (BRAF)" *J. Med. Chem.*; **2009**; *52*; 2255-2264

25. Lucchini, V.; Borsato, G.; Canovese, L.; Santo, C.; Visentin, F.; Zambon, A.. "Qualitative and quantitative discrimination of fake and true alkene rotation processes in Pd(.eta.2-olefin) complexes. A new bimolecular mechanism." *Inorganica Chimica Acta*, **2009**, *362*, 2715-2721

26. Puttini, M.; Redaelli, S.; Moretti, L.; Brussolo, S.; Gunby, R. H.; Mologni, L.; Marchesi, E.; Cleris, L.; Donella-Deana, A.; Drücke, P.; Sala, E.; Lucchini, V.; Kubbutat, M.; Formelli, F.; Zambon, A.; Scapozza, L.; Gambacorti-Passerini, C. " Characterization of cmp-584, an Abl kinase inhibitor with lasting effects" *Haematologica,* **2008**, *93,* 653-61

27. Zambon, A.; Borsato, G.; Frascella, P.; Brussolo, S.; V. Lucchini "Efficient access to 5-substituted thiazoles by a novel metallotropic rearrangement" *Tetrahedron Lett.,* **2008**, *49*, 66-69

28. Kuettel, S.; Zambon, A.; Kaiser, M.; Brun, R.; Scapozza, L.; Perozzo, R. "Synthesis and Evaluation of Antiparasitic Activities of New 4-[5-(4-Phenoxyphenyl)-2H-pyrazol-3-yl]morpholine Derivatives" *J. Med. Chem.*; **2007**; *50*; 5833-5839

29. Borsato, G.; Linden, A.; De Lucchi, O.; Lucchini, V.; Wolstenholme, D.; Zambon, A.; "Chiral Polycyclic Ketones via Desymmetrization of Dihaloolefins" *J. Org. Chem.*, **2007**, *72,* 4272-4275

30. Sarno, S.; Ruzzene, M.; Frascella, P.; Pagano, M. A.; Meggio, F.; Zambon, A.; Mazzorana, M.; Di Maira, G.; Lucchini, V.; Pinna, L. A. "Development and exploitation of CK2 inhibitors" *Molecular and Cellular Biochemistry,* **2005**, *27,* 69–76

31. Borsato, G.; Crisma, M.; De Lucchi; O.; Lucchini, V.; Zambon A.; " "Hexacarboxytrindanes": Benzene Rings with Homotopic Faces as Scaffolds for the Construction of D3 Chiral Architectures" *Angew. Chem. Int. Ed.,* **2005**, *44*, 7435 –7439

32. Argese, E; Bettiol , C.; Marchetto, D.; De Vettori, S.; Zambon, A.; Miana, P.; Ghetti, P.F.; "Study on the toxicity of phenolic and phenoxy herbicides using the submitochondrial particle assay" *Toxicology in Vitro,* **2005***, 19*(8)*,* 1035-1043

33. Borsato, G.; Brussolo, S.; Crisma, M.; De Lucchi; O.; Lucchini, V.; Zambon A.; "Tris-annelated benzenes Selectively perfuncionalized on one side only: hexachloronorbornadiene as a versatile scaffold for the construction of molecular domes" *Synlett,* **2005**, *7*, 1125-1128

34. Borsato, G.; Negra, F. D.; Gasparrini, F.; Misiti, D.; Lucchini, V.; Possamai, G.; Villani, C.; Zambon, A.; " Internal Motions in a Fulleropyrrolidine Tertiary Amide with Axial Chirality" *J. Org. Chem.;* **2004**; *69*(17); 5785-5788.

35. Borsato, G.; Lucchini, V.; Modena, G.; Pasquato, L.; Zambon A.; "Nucleophilic reactions at the ring carbons of thiiranium and thiirenium ions. An experimental and theoretical comparison of the SN2 and SN2-*Vin* mechanisms" *Arkivoc,* **2003**, *xii*, 38-55

36. Borsato, G.; De Lucchi, O., Fabris, F.; Lucchini, V.; Frascella, P.; Zambon, A.; "Synthesis and evaluation of new chiral diols based on the dicyclopentadiene skeleton" *Tetrahedron Lett.*, **2003**; *44,* 3517-3520

37. Borsato, G.; De Lucchi; O., Fabris, F.; Lucchini, V.; Pasqualotti, M.; Zambon, A. "Synthesis of the *syn* and *anti* isomer of 1,4,5,8,9,12-hexahydro-2,3,6,7,10,11-hexamethylidene-1,4:5,8:9,12- trimethano triphenylene and Diels–Alder reactivity of the *syn* isomer" *Tetrahedron Lett.*, **2003**; *44*, 561-563

38. Borsato, G.; De Lucchi, O.; Fabris, F.; Groppo, L.; Lucchini, V.; Zambon, A. "Efficient cyclotrimerization of bicyclic *vic*-bromostannylalkenes promoted by Copper(I) Thiophen-2- carboxylate" *J. Org. Chem.*, **2002**; *67*; 7894 -7897

39. Argese, E.; Bettiol, C.; Fasolo, M.; Zambon, A. Agnoli, F. "Substituted aniline interaction with submitochondrial particles and quantitative structure-activity relationships" *Biochim. Biophys. Acta Biomembranes*, **2002**, *1558,* 151-160

40. Canovese, L.; Lucchini, V.; Santo, C.; Visentin, F.; Zambon, A. "A novel mechanism for the fluxional behaviour of [Pd(□2-tetramethylethylenetetracarboxilate) (2-methylthiomethyl pyridine)]" *J. Organomet. Chem.* **2002**, *642*, 58-63

41. Kordatos, K.; Bosi, S.; Da Ros, T.; Zambon, A.; Lucchini, V.; Prato, M. "Isolation and characterization of all eight bisadducts of fulleropyrrolidine derivatives" *J. Org. Chem.*, **2001**, *66*, 2802 -2808

42. Argese, E.; Bettiol, C.; Agnoli, F.; Zambon, A.; Mazzola, M.; Volpi A. "Assessment of chloroaniline toxicity by the submitochondrial particle assay" *Envirom. Toxicol. Chem.*, **2001**, *20*, 826–832

43. Trombetta, M.; Busca, G.; Storaro, L.; Lenarda, M.; Casagrande, M.; Zambon, A. "Surface acidity modifications induced by thermal treatments and acid leaching on microcrystalline H-BEA zeolite. A FTIR, XRD and MAS-NMR study*" Phys. Chem. Chem.*

Phys., **2001**, *15*, 3529-3537